AIM ImmunoTech highlights Ampligen preclinical data for Ebola preparedness

AIM ImmunoTech Inc.

Video discusses Ampligen as prophylactic/early-onset treatment for Bundibugyo Ebola strain with no approved therapies.
Preclinical findings: 100% protective survival with early Ampligen administration in lethal Ebola mouse model.
Ampligen has orphan drug designation from FDA and EMA for Ebola virus disease.
Updated Ebola-focused corporate presentation available on company website.
CEO Thomas Equels noted urgent need for therapeutic in ongoing outbreak.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.